The Aberrant Expression Levels of miR-423-5p and miR-664b-5p in Peripheral Blood of Patients With Familial and Sporadic Ovarian Carcinoma

2020 ◽  
Author(s):  
BUSRA KURT ◽  
Seref Bugra TUNCER ◽  
Demet AKDENIZ ODEMIS ◽  
Arash ADAMNEJAD GHAFOUR ◽  
Mukaddes Avsar Sarali ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patient ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
Ovarian Cancer Patient ◽  
Expression Level ◽  
Control Group ◽  
Second Primary ◽  
Aberrant Expression ◽  
Significant Difference

Abstract MicroRNAs (miRNAs), are endogenous noncoding single strand RNA molecules with approximate length of 22 nucleotides. Ovarian cancer is a heterogenous disease which includes different biologic behaviors in the clinical, and molecular level. miRNAs have roles in the early diagnosis, prognosis, and chemotherapy sensitivity for ovarian cancer, and in the regulation of reproduction by being expressed in the ovaries. The expression level of two miRNAs of miR-423-5p, and miR-664b-5p selected from the miRNAs which were detected to be important for the ovarian cancer etiology in our previous studies were investigated in the peripheral blood of familial and sporadic ovarian cancer patients, and in healthy individuals. The expression analyses were statistically evaluated with SPSS v21.0 program using the Quantitative Real-Time PCR technique. A statistically significant difference was detected for both miRNAs between the healthy controls and ovarian cancer patient groups (p:0.000). The miR-423-5p expression was detected to increase 2.35 fold, and miR-664b-5p was detected to increase 2.47 fold in ovarian cancer patients compared with the levels in the control group. miR-423-5p was reported to be overexpressed in various cancer types, and in different disease stages in previous study, and miR-423-5p was demonstrated to have increased in the lymphocytes in the peripheral circulation of ovarian cancer patients first in our literature. The miR-664b-5p expression level was detected in high levels in ovarian cancer patient group, however was detected to have decreased in 64% of ovarian cancer patients with BRCA mutation carrier. The expressions of both miRNA molecules were detected to have decreased in the ovarian cancer subgroups in patients with ovarian cancer with addition of a second primary cancer of endometrium cancer, however, were detected in the highest level in ovarian cancer patients in addition to another secondary cancer except breast and endometrium cancer. The results obtained from the study showed that the increased expression of both miRNA molecules were suggested to be associated with ovarian cancer, and decrease was suggested to be associated with endometrium cancer. In summary, the miRNA molecules in the present study might be the non-invasive biological indicator in ovarian cancer, and the demonstration of these molecules on the tumor tissue, and their change during treatment in future studies will be beneficial.

scholarly journals High Level of Mir-142-3P Expression in Peripheral Blood of Patients with Ovarian Carcinoma

2021 ◽  
Author(s):  
Yasemin Gider ◽  
Xhariga Jabbarli ◽  
Gamze Uyaroglu ◽  
Seref Bugra Tuncer ◽  
Demet Akdeniz Odemis ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Late Stage ◽  
Peripheral Blood ◽  
Poor Prognosis ◽  
Expression Level ◽  
Healthy Control Group ◽  
Control Group ◽  
Healthy Controls ◽  
Healthy Control

Abstract Background The most common cancers detected in women are breast, thyroid, colorectal, uterine corpus, lung, and ovarian cancer. Ovarian cancer is responsible from more than 150.000 death annually worldwide. This cancer is detected in the late stage, and is characterised with poor prognosis, therefore most cases result with death. The fact that this cancer manifests itself in the late stage and is characterized by a poor prognosis, is caused death in the majority of cases. Therefore, the diagnosis and the treatment of the disease have to be improved for a better quality of life for patients. MicroRNAs are the noncoding RNAs in the length of 19–24 nucleotides which show suppressor effect on target genes. miRNAs are included in the pathology of various diseases including cancer. miRNAs being as the biomarker candidates in diagnosis, and their use in treatment as the inhibitors of the molecules mimicking the miRNA showed that they may be used as the new therapeutic target and agents. Methods We detected with our group in our prior study conducted with disconcordant ovarian cancer twins that many miRNA molecules were different in ovarian cancer compared with the molecules in healthy sibling. The expression level of miR-142-3p that was selected from the miRNAs detected in the previous study was compared, and investigated in a wider ovarian cancer group, and in healthy control group. miR-142-3p expression level was investigated using the real-time PCR method in the present study involving 147 patients, and 100 healthy control group. The differences in the expression levels of miR-142-3p detected in the peripheral blood lymphocytes of ovarian cancer patients, and healthy control were statisticaly evaluated. Results The expression level of miR-142-3p was detected to have increased 3.11 fold in ovarian cancer patients compared with the levels in healthy controls, and the difference was statistically significant (p:0.00). These results suggest that miR-142-3p that was found significantly increased in the peripheral blood samples of ovarian cancer patients compared with the healthy controls might be used as a sensitive, noninvasive biomarker in the early diagnosis, and treatment and follow up of ovarian cancer.

scholarly journals High Expression Level of miR-1260 Family in the Peripheral Blood of Patients with Ovarian Carcinoma

2020 ◽  
Author(s):  
Arash Adamnejad Ghafour ◽  
Demet Akdeniz Odemis ◽  
Seref Bugra Tuncer ◽  
Busra Kurt ◽  
Mukaddes Avsar Sarali ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cervical Cancer ◽  
Cancer Treatment ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
Uterine Cancer ◽  
Expression Level ◽  
Control Group ◽  
Gynecologic Cancers ◽  
Expression Levels

Abstract The most common gynecologic cancers detected in women in Turkey are uterine cancer, ovarian cancer, and cervical cancer. These data reported that a mean of 3800 individuals were diagnosed with uterine cancer, 2790 were diagnosed with ovarian cancer, and 1950 were diagnosed with cervical cancer, and 400 individuals were diagnosed with other gynecologic cancers each year in Turkey. A mean of 14.270 individuals were detected to have been diagnosed with gynecologic cancers each year in the United States of America(USA). Ovarian cancer treatment is generally composed of chemotherapy, and surgery. In general, chemotherapy is administered after surgery. The identification of the molecular pathogenesis of ovarian cancer, and discovery of new moleculer biomarkers which facilitate the ovarian cancer treatment are required for an effective ovarian cancer treatment in clinics. miRNAs are reported to be the possible biologic indicators for various cancer types. We aimed to investigate 2 miRNAs which were suggested to have effect in ovarian cancer in our (previous)monozygotic twin study from miR-1260 microRNA family whose association with ovarian cancer yet has not been reported in the literature. We investigated the expression levels of miR-1260a, and miR-1260b miRNAs, in the peripheral blood lymphocytes of 150 familial and sporadic ovarian cancer patients, and of 100 healthy individuals of the control group who were matched for age, sex, and ethnicity with the patient group, and investigated their possible property of being a biologic indicator for ovarian cancer. The expression results of ovarian cancer patients were evaluated by comparison of the results of the control group in the study. The expression levels of miR-1260a, and miR-1260b in ovarian cancer patients were found highly increased compared with the levels in the control group. miR-1260a expression level in ovarian cancer patients was detected to have increased approximately 17 fold compared with the control group, and miR-1260b expression level in ovarian cancer patients was detected to have increased approximately 33 fold compared with the levels in the control group. The String Analyses showed that the miR-1260a was associated with the ribosomal protein family which was known to be effective in the translation stage of cell and that miR-1260b was associated with CHEK2 protein which was a member of the serine/threonine-protein kinase family. It should be investigated for larger cohorts in benign ovarian diseases and in different stages of patients receiving ovarian cancer treatment whether these two molecules are a noninvasive biomarker and therapeutic target to be used especially in the early diagnosis and prognosis of ovarian cancer in future.

scholarly journals High expression level of miR-1260 family in the peripheral blood of patients with ovarian carcinoma

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Arash Adamnejad Ghafour ◽  
Demet Akdeniz Odemis ◽  
Seref Bugra Tuncer ◽  
Busra Kurt ◽  
Mukaddes Avsar Saral ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cervical Cancer ◽  
Cancer Treatment ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
Uterine Cancer ◽  
Expression Level ◽  
Control Group ◽  
Gynecologic Cancers ◽  
Expression Levels

AbstractThe most common gynecologic cancers detected in women in Turkey are uterine cancer, ovarian cancer, and cervical cancer. These data reported that a mean of 3800 individuals were diagnosed with uterine cancer, 2790 were diagnosed with ovarian cancer, and 1950 were diagnosed with cervical cancer, and 400 individuals were diagnosed with other gynecologic cancers each year in Turkey. A mean of 14.270 individuals were detected to have been diagnosed with gynecologic cancers each year in the United States of America (USA). Ovarian cancer treatment is generally composed of chemotherapy, and surgery. In general, chemotherapy is administered after surgery. The identification of the molecular pathogenesis of ovarian cancer, and discovery of new moleculer biomarkers which facilitate the ovarian cancer treatment are required for an effective ovarian cancer treatment in clinics. miRNAs are reported to be the possible biologic indicators for various cancer types. We aimed to investigate 2 miRNAs which were suggested to have effect in ovarian cancer in our (previous) monozygotic twin study from miR-1260 microRNA family whose association with ovarian cancer yet has not been reported in the literature. We investigated the expression levels of miR-1260a, and miR-1260b miRNAs, in the peripheral blood lymphocytes of 150 familial and sporadic ovarian cancer patients, and of 100 healthy individuals of the control group who were matched for age, sex, and ethnicity with the patient group, and investigated their possible property of being a biologic indicator for ovarian cancer. The expression results of ovarian cancer patients were evaluated by comparison of the results of the control group in the study. The expression levels of miR-1260a, and miR-1260b in ovarian cancer patients were found highly increased compared with the levels in the control group. miR-1260a expression level in ovarian cancer patients was detected to have increased approximately 17 fold compared with the control group, and miR-1260b expression level in ovarian cancer patients was detected to have increased approximately 33 fold compared with the levels in the control group. The String Analyses showed that the miR-1260a was associated with the ribosomal protein family which was known to be effective in the translation stage of cell and that miR-1260b was associated with CHEK2 protein which was a member of the serine/threonine-protein kinase family. It should be investigated for larger cohorts in benign ovarian diseases and in different stages of patients receiving ovarian cancer treatment whether these two molecules are a noninvasive biomarker and therapeutic target to be used especially in the early diagnosis and prognosis of ovarian cancer in future.

Pro- and Antiapoptotic Proteins Expression on Bone Marrow and Peripheral Blood CD34+Cells in Acute Leukemia (AL) Patients

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4996-4996
Author(s):  
Elena E. Khodunova ◽  
Elena N Parovichnikova ◽  
Irina V. Galtzeva ◽  
Sergey M. Kulikov ◽  
Valeri G Savchenko
Keyword(s):  
Bone Marrow ◽  
Peripheral Blood ◽  
Conflicts Of Interest ◽  
Expression Level ◽  
Leukemia Cells ◽  
Control Group ◽  
Healthy Donors ◽  
Cd34 Cells ◽  
Significant Difference ◽  
Blast Cells

Abstract Abstract 4996 It was shown that drug resistance, poor-risk cytogenetics and poor prognosis in AL is associated with high level of Bcl-2 expression and low Bax/Bcl-2 ratio (<0,3). Fas-antigen (CD95) as a protein triggering the extrinsic apoptotic pathway is differently expressed on hematopoietic precursors. More immature CD34+/CD38- AML blast cells have lower expression of Fas/Fas-L and lower Fas-induced apoptosis than CD34+/CD38+cells. CD34+/CD38− leukemia precursors also have a reduced sensitivity to daunorubicin in vitro and increased expression of multidrug resistance genes (mrp/lrp). CD34+ leukemia cells have not yet been properly characterized regarding the expression of angiotensin converting enzyme (ACE) which regulatory influence on hematopoiesis is now beeing extensively investigated. ACE expression on blast cells is high, but it's still unknown how CD34+ACE+ leukemia cells behave after chemotherapy. Recent publications indicate that CD34+ACE+ hematopoietic precursors transplanted into NOD/SCID mice contribute 10-fold higher numbers of multilineage blood cells than their CD34+ACE- counterparts. We have studied the dynamics of Bcl-2, Bax, CD95 and ACE expression on CD34+ cells in peripheral blood (PB) and bone marrow (BM) in AL pts during treatment. PB and BM samples were collected before and on +36 day after chemotherapy. The antigens were detected by flow cytometry using monoclonal antibodies. We calculated 10 000 cells in each sample. 19 pts were included in the study: 10 - AML and 9 - ALL. The control group comprised 8 healthy donors. At time of diagnosis there were 40±5,7% of CD34+ cells in BM and 26±4,9% - in PB. There was no significant difference between AML and ALL. CD34+ cells in BM and PB of healthy donors constituted 1,6% and 0,27%, respectively. After induction therapy (+36 day) CD34+ cells decreased in BM to 6,1%±3,3 (p=0,0001), in PB to 3,7%± 2,7 (p=0,0008) in all pts. The data on antigens expression on CD34+ cells of BM and PB are presented in table 1 CD34+/Bcl-2+ CD34+/Bax+ CD34+/CD95+ CD34+/ACE+ BM PB BM PB BM PB BM PB AML pts n=10 0 day 38±11,6* 41±14 24,4±7,9 29,2±7,6* 16,4±8,5 23,2±7,8 21,7±9,5 20,8±8,7* 36 day 13,5±3,4** 23,7±5** 46,2±11,5 50,3±11 19,9±5,5 36,4±10 34±6,6 35±9,2** ALL pts n=9 0 day 36±11 33,7±12 46,2±9,4 37,4±3,7* 3,4±1,1* 7,1±2,5* 41±10,9 33,2±9,7* 36 day 18,4±5,8 26±8,9 38±11,8 40,5±10 26,2±9,1** 40,9±9,2** 34±10 62,8±10** Donors n=8 11,7±1,6 26,1±5,9 22,8±4 67,8±6,7 13,4±3,2 47,7±11,6 28±5,3 68,2±10,2 * − p<0.05 compare with donors ** − p<0.05 compare with day 0 CD34/Bcl-2 expression in BM in AML pts is significantly higher (p=0,04) at the diagnosis comparing with donors. CD34/Bcl-2 expression in PB in AML pts and in BM and PB in ALL pts is higher too, but not significantly. This expression level decreased substantially in BM and PB in AML pts on +36 day comparing with day 0 (p<0,05). We did not found significant changes in ALL pts. CD34/Bax expression in PB is significantly lower (p=0,003) both in AML and ALL pts in comparison with donors. In AML, not in ALL, chemotherapy caused augmentation of Bax expression in CD34+ BM and PB cells on +36 day. BM and PB CD34+ cells in donors had different expression characteristics of Bcl-2 and Bax, demonstrating much higher level of pro- and antiapoptotic markers in PB cells. On the contrast CD34+ leukemia cells in BM and PB had similar characteristics regarding CD34/Bcl-2 and CD34/Bax expression. This fact demonstrates the heterogeneity of donor CD34+cells in BM and PB and points that leukemia CD34+cells in BM and PB are rather similar. CD95 expression on CD34+ BM and PB before treatment is significantly lower (p=0,01, p=0,008) in ALL pts in comparison with donors, and this expression level increased after chemotherapy (p<0,05). CD34/CD95 expression in AML pts is similar with donors, and we didn't find changes after treatment. CD34/ACE coexpression in BM cells of leukemia pts and donors did not differ much at any time of evaluation. But CD34/ACE expression in PB cells of AML and ALL pts was much lower (p<0,05) than in donors and substantially increased on the day 36. So, our data demonstrate that Bcl-2, Bax, CD95 and ACE expression on CD34+ cells in AL pts and donors significantly differs. The chemotherapy provokes critical changes in CD34/CD95 expression in BM and PB in ALL pts, CD34/Bcl-2 expression in AML pts and ÑÂ34/ACE expression in PB in all AL pts. Disclosures: No relevant conflicts of interest to declare.

Long Non-Coding RNA- PVT1 in Ovarian Cancer as Predictors for Platinum Analogues Resistance

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Walid Abd Almonem Biomy ◽  
Mohamed Yassin Mostafa ◽  
Nashwa Nagy EL-Khazragy ◽  
Khaled Kamal Eldein Ghonem ◽  
Amr Attia Hewety
Keyword(s):  
Ovarian Cancer ◽  
Retrospective Study ◽  
Cancer Patients ◽  
Complete Blood Count ◽  
Ovarian Tissue ◽  
Treatment Modalities ◽  
Control Group ◽  
Presenting Symptoms ◽  
Significant Difference ◽  
Normally Distributed

Abstract Background Ovarian cancer is the fifth most common type of cancer and the most common cause of death among women with gynecological malignancies. Objectives The aim of this retrospective study was to assess expression of the Lnc_PVT1 in the studied subjects. The expression of Lnc_PVT1 biomarker; was compared in ovarian cancer patients versus the non-cancerous tissue. The data normalization was tested by normality test which shows that the biomarker expression is not normally distributed; thus, a Mann Whitney statistics test for non -parametric values was applied. Our results showed a high significant difference in the expression of Lnc-PVT1 (p &lt; 0.01). Lnc_PVT1 expression is upregulated by 2.4 folds in ovarian cancer patients (median: 32.0; range: 11 – 92) compared to control group (median: 13.0; range: 11 – 16). Methods and Materials This is a retrospective study. Include patients with advanced epithelial ovarian cancer (stage II and IV) who received chemotherapy platinum based and taxines from 2014-2017. Setting: Clinical oncology department Ain Shams University, Egypt, Demerdash hospital. Data collection: The following information will be ANONYMOUSLY extracted from the patient medical files: age at diagnosis, presenting symptoms, laboratory investigations: (Liver function, kidney function, complete blood count &tumor markers), tumor histological type, tumor FIGO stage& degree of differentiation, treatment modalities, type of surgery, chemotherapy regimens (Adjuvant, Neoadjuvant or palliative), chemotherapy responsiveness or resistance, disease recurrence and disease-free period, and patients' survival. Results The current study was enrolled on 55 subjects, they classified into two subgroups. The ovarian cancer cases constitute 45 patients; samples collected from patients after diagnosis has been confirmed by histopathology based on immune-histochemical analysis as well as Computerized axial tomography (CT scan) and Magnetic resonance imaging (MRI). The cancer ovary patients were compared to ten non- malignant ovarian tissues. Table 1 illustrates the demographic and clinical data of the studied subjects. We test the normality for age; the data was normally distributed. For this reason, we represent the data in mean value and standard deviation form. Matched age and gender was observed between ovarian cancer patients and healthy control. The mean age for the studied subjects was 47.7±9.1. In our study; the Cisplatin resistant patients (n = 25) had a mean age of 46±5 compared to Cisplatin sensitive which were older (mean: 50 ±11.5). Regarding the age subgroups; the majority of the studied subjects were younger than 48 years old. The ovarian cancer patients were subcategorized into subgroups (Cisplatin sensitive/resistant). Conclusion Comparative analysis between Cisplatin sensitive and resistant ovarian cancer tissues for the Lnc_PVT1, TGF-b and Caspase-3. A high significant difference was observed by Mann- Whitney test (p = 0.001) between Cisplatin sensitive and resistant ovarian cancer patients; Cisplatin resistant tissues showed higher expression levels of the Lnc_PVT1 expression (median 20.0, range: 10 - 92) in Cisplatin sensitive ovarian tissue compared to Cisplatin resistant tissue (median: 83; range: 46-86).

Epidemiology of Second Primary Tumors in Women With Ovarian Cancer

2017 ◽  
Vol 27 (4) ◽  
pp. 659-667 ◽  
Author(s):  
Tomi T. Kanninen ◽  
Dimitrios Nasioudis ◽  
Giovanni Sisti ◽  
Kevin Holcomb ◽  
Mariarosaria Di Tommaso ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
General Population ◽  
Cancer Patients ◽  
Elevated Risk ◽  
Second Primary ◽  
Ovarian Malignancy ◽  
Primary Tumors ◽  
Significant Difference ◽  
Second Primary Tumors ◽  
End Results

ObjectiveThe last large study of second primary tumors (SPTs) in women with ovarian cancer was published in 1996, prior to major changes in the differential diagnosis and treatment. The present study reports on the incidence of SPTs in a contemporary cohort of patients with a diagnosis of ovarian cancer.MethodsOvarian cancer patients with a diagnosis of an ovarian malignancy between 1992 and 2012 were identified and characterized from 13 registries of the Surveillance, Epidemiology, and End Results database.ResultsOf 41,073 women with a diagnosis of an ovarian malignancy between 1992 and 2012, 1831 (4.5%) developed a microscopically confirmed SPT. There was no significant difference in the risk of developing an SPT at all sites between women with an ovarian cancer and the general population. There was an elevated risk of site-specific SPTs of the small intestine, vagina, thyroid gland, and acute nonlymphocytic leukemia in ovarian cancer patients compared with the general Surveillance, Epidemiology, and End Results population. Conversely, the risk of lung and non-Hodgkin lymphoma was significantly decreased in women with ovarian cancer. An elevated risk of SPTs was observed in women with mucinous, endometrioid, and germ cell tumors. White women had an overall decreased risk of developing a second primary solid tumor, whereas American Indian and Asian/Pacific Islander women had an overall increased risk of an SPT at any site.ConclusionsThe incidence of SPTs in women with ovarian cancer was not significantly different as compared with the general population. However, divergent rates of SPTs in relation to histology, latency, age, and race were observed.

Success Rate of Obturation of Root Canals by Different Techniques in Primary Molars: A Comparative Clinical Study

2020 ◽  
Vol 2 (1) ◽  
pp. 36-44
Author(s):  
Satyawan G. Damle ◽  
Ritika Bansal ◽  
Dhanashree D. Sakhare
Keyword(s):  
Success Rate ◽  
Study Groups ◽  
Primary Molars ◽  
Control Group ◽  
Second Primary ◽  
Chi Square ◽  
Exact Test ◽  
Root Canals ◽  
Significant Difference ◽  
Comparative Clinical Study

Objective: To compare the success rate of different obturation procedures in primary mandibular second molars clinically and also by digital radiovisiography. Methods: A total of 40 children aged between 4-8 years with deeply carious mandibular second primary molars indicated for single session pulpectomy were selected. Canals were obturated with Metapex. The 3 study groups (Endodontic plugger, Handheld lentulospiral, Navi Tip syringe) were compared with the control group (reamer) both clinically and radiovisiographically. The data collected were statistically analyzed using Pearson’s Chi-square and Fisher’s exact test. Results: The use of Navi tip syringe led to the least number of voids followed by Endodontic plugger and Reamer and the highest number of voids was reported with Lentulospiral. Navitip presented maximum number of optimally filled cases followed by Endodontic plugger and Lentulospiral and least number of optimally filled cases with reamer. However, there was no statistically significant difference (p>0.05) in any of the groups with clinical (pain and tenderness to percussion) and radiographic parameters (presence or absence of voids and length of obturation). Conclusion: Within the limitations of the present study, though the clinical outcome was statistically insignificant, Navitip syringe exhibited encouraging results and is a promising option for obturation in primary teeth.

The effect of foot reflexology on chemotherapy-induced nausea and vomiting in digestive or lung cancer patients: a randomized controlled trial (Preprint)

2020 ◽  
Author(s):  
Audrey Murat-Ringot ◽  
Pierre Jean Souquet ◽  
Fabien Subtil ◽  
Florent Boutitie ◽  
Marie Preau ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Controlled Trial ◽  
Nausea And Vomiting ◽  
Control Group ◽  
Digestive Cancer ◽  
Complementary Medicines ◽  
Antiemetic Drugs ◽  
Platinum Based Chemotherapy ◽  
Significant Difference ◽  
Delayed Nausea

BACKGROUND Cancer is a chronic disease with an incident worldwide had been 24.5 million and 9.6 million deaths in 2017. Lung and colorectal cancer are the most common cancer for both sexes and according to national and international recommendations platinum-based chemotherapy is the reference adjuvant treatment. This chemotherapy can be moderately to highly emetogenic. Despite antiemetic therapy, chemotherapy-induced nausea and vomiting may persist. Moreover, cancer patient are increasingly interested in alternative and complementary medicines and express the desire that non-pharmacological treatments be used in hospitals. Among alternative and complementary medicines, foot reflexology decreases significantly the severity of chemotherapy-induced nausea and vomiting in breast cancer patients. OBJECTIVE The primary objective of the present study was to assess the benefits of foot reflexology as a complement to conventional treatments on severity of acute chemotherapy-induced nausea and vomiting in digestive or lung cancer patients. The secondary objectives assessed were the frequency and severity of delayed chemotherapy-induced nausea and vomiting, quality of life, anxiety, and self-esteem. METHODS The present study was conducted between April 2018 and April 2020 in French University Hospital. This is an open-label randomized controlled trial. Participants are randomized into two groups: 40 to interventional group (conventional care with foot reflexology) and 40 to control group (conventional care without foot reflexology). Foot reflexology sessions (30 minutes) are performed on an outpatient or inpatient. Eligible participants are patients with a lung or digestive cancer with indication for platinum-based chemotherapy. RESULTS The severity of acute nausea and vomiting was assessed with a visual analogue scale during the second cycle of chemotherapy. A significant increase of at least 2 points was observed for control group (20.6%, P = 0.01). Across all cycle, the foot reflexology group showed a trend towards less frequent delayed nausea (P=0.28), a significantly less frequent consumption of antiemetic drugs (P=0.04), and no significant difference for vomiting (P=0.99); there was a trend towards a perception of stronger severity for delayed nausea in the control group (P=0.39). According to quality of life and anxiety, there was no significant difference between the interventional group and the control group (P=0.32 and P=0.53 respectively). CONCLUSIONS In conclusion, the present study results indicated that foot reflexology decreased significantly the severity of acute nausea and consumption of antiemetic drugs in lung and digestive cancer patients. No side effects from foot reflexology have been noted. In order to better respond to a desire of patients for non-pharmacological treatments and CAMs to be used in hospitals to improve their care, the results of this study showed that foot reflexology seems to be a promising complement to conventional antiemetic drugs. To assess the performance of this intervention in routine practice, a larger study with several health care centers would be relevant with a cluster RCT. CLINICALTRIAL The present study registered with clinicaltrials.gov: NCT03508180 (28/06/2018) INTERNATIONAL REGISTERED REPORT RR2-10.2196/17232

Sign in / Sign up

Export Citation Format

Share Document